News
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Novo now expects 2025 sales growth of 8%-14% in local currencies, down from its previous 13-21% range. It also lowered its ...
Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales ...
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...
9h
Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...
A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback